All News

APR video gout cover

Gout

Jack Cush, MD

Dr. Jack Cush reviews Gout in this continuing series for Advanced Practice Rheum.

Read Article
EULAR19.abstract.jpg (keep)

EULAR 2026: Industry Press Releases

Jack Cush, MD

Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.

Read Article
PsA.Xray_.Erosion.Cup_.jpg

Guselkumab gets FDA Nod for X-ray Protection

Jack Cush, MD

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). 

Read Article
RheumNow Podcast square

Count Your Telangiectasias (5.29.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and missed quiz questions.

Read Article
drug%20interactions.jpg

Increased Polypharmacy in SLE Patients

Jack Cush, MD

A cross-sectional study of US adults with systemic lupus erythematosus (SLE) shows significantly increased prevalence of polypharmacy, related to age, disease outcomes and often, non-SLE common medications.

Read Article
T2T.RA2_.jpg

Integrating D2T into T2T Practices in RA

EurekAlert!

Researchers at Semmelweis University analyzed how depression, smoking, obesity, sleep disorders, and other health problems are linked to difficult-to-treat rheumatoid arthritis (D2T-RA) and how this can inform treat-to-target (T2T) and individualized therapy.

Read Article
LRA.logo

LRA Awards for Immune Resetting Therapies in Lupus

Lupus Research Alliance

Lupus Research Alliance (LRA), the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of t

Read Article
💉 Add tirzepatide to biologics in obese #PsA? #POS0050: Yes! Propensity score-matched study (n=93): better PROs, HAQ & PASI at 6 months #EULAR2026 @RheumNow @vincevenerito https://t.co/rrhNKZByjc

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Pts with AIIRD carry a high risk & burden of infection due to immune dysregulation, comorbids, GC/DMaRD use. As a rheumatologist, do you vaccinate your patients? #EULAR2026 @RheumNow

sheila RHEUMarampa ( View Tweet)

#Vaccination in Rheum 📍Hold MTX 1-2wks post vax 📍For Bcell depleters, timing is based on B-cell repop’n kinetics, not fixed calendar intervals. THM: Assess vax need at dx, vax w/o delay #EULAR2026 @RheumNow https://t.co/6ptl8gyBLR

Links:

sheila RHEUMarampa ( View Tweet)
Advanced Practice Rheum: Safety of Biologics and Novel Agents Dr. Jack Cush reviews safety of biologics and novel agents. This video is part of the Advanced Practice Rheum series. https://t.co/K5TiwFA0L2 https://t.co/XoFsTMnxPC

Links:

Dr. John Cush RheumNow ( View Tweet)
Curcumin in arthritis may have NSAID like clinical efficacy. But how? Metanalysis lays out the multiple potential effects for it to inhibit inflammatory signaling pathways (NF-κB, TNF-α, IL-1β, IL-6, COX-2, and PGE2) https://t.co/gSYVwpl41P https://t.co/0xZdyiF4QN

Links:

Dr. John Cush RheumNow ( View Tweet)
RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's A small pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease. https://t.co/eeyhso0WJ6 https://t.co/ZGWOOtf92E

Links:

Dr. John Cush RheumNow ( View Tweet)
True or False: After successfully treating herpes zoster, it is considered safe to restart anti-TNF therapy without a significant risk of recurrence. See if you got it right in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/pGggdVPhmh

Links:

Dr. John Cush RheumNow ( View Tweet)
In the cross-sectional study of US SLE patients, what was the most common drug class driving polypharmacy beyond SLE medications? Test your knowledge in this week's RheumIQ quiz at https://t.co/DX0qT1iNF2 https://t.co/ox4rGp04WH

Links:

Dr. John Cush RheumNow ( View Tweet)
Adverse drug events (ADEs) studied in autoimmune rheum Dz (ARDs). In 10,578 ARD pts 30% had 1+ ADE, highest in SSc (36%). Polypharmacy (57.3% minor, 39.4% major) contrib to increasing ADEs. ADEs were more from Sx Rx (antacids, Tylenol, psychotropics) than DMARDs. https://t.co/BOAfU1DyIN
Dr. John Cush RheumNow ( View Tweet)
RepurpSS-II: Hydroxychloroquine plus Leflunomide in Sjögren's A small pilot, phase 2b trial has shown that the combination of leflunomide and hydroxychloroquine (LEF+HCQ) was effective and safe in treating patients with active Sjögren's disease. https://t.co/tyd1efUtca https://t.co/zcY7RyX8SZ

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUM SURVEY> Per 2024 EULAR Guidelines, an active RA pt on MTX who fails a 1st TNFi, should next change to ?

Dr. John Cush RheumNow ( View Tweet)

RHEUM SURVEY> Per 2024 EULAR Guidelines, an active RA pt on MTX who fails a 1st TNFi, should next change to ?

Dr. John Cush RheumNow ( View Tweet)

The safe/right choice is H. Zoster. You never fully eradicate invasive fungal or NTM infections. HBV is too risky to again use TNFi again. After H.zoster is Rx,there is evidence its safe to restart TNFi without risk of recurrence. Vagal N. Stim is the mechanistically same as

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×